questionsmedicales.fr
Cellules
Cellules épithéliales
Hépatocytes
Cellules HepG2
Cellules HepG2 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Carcinome hépatocellulaire
Lignées cellulaires
Culture cellulaire
Microscopie
Symptômes
2
Symptômes
Cellules in vitro
Marqueurs tumoraux
Enzymes hépatiques
Prévention
2
Prévention des maladies
Composés bioactifs
Recherche préventive
Toxines
Traitements
2
Essais cliniques
Toxicité
Développement de médicaments
Mécanismes d'action
Complications
2
Mécanismes pathologiques
Complications hépatiques
Facteurs de risque
2
Facteurs de risque
Toxines
Évaluation des risques
Agents toxiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cellules HepG2 : Questions médicales les plus fréquentes",
"headline": "Cellules HepG2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cellules HepG2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-11",
"dateModified": "2025-02-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cellules HepG2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hépatocytes",
"url": "https://questionsmedicales.fr/mesh/D022781",
"about": {
"@type": "MedicalCondition",
"name": "Hépatocytes",
"code": {
"@type": "MedicalCode",
"code": "D022781",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.436.348"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cellules HepG2",
"alternateName": "Hep G2 Cells",
"code": {
"@type": "MedicalCode",
"code": "D056945",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Wilson de Melo Cruvinel",
"url": "https://questionsmedicales.fr/author/Wilson%20de%20Melo%20Cruvinel",
"affiliation": {
"@type": "Organization",
"name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com."
}
},
{
"@type": "Person",
"name": "Paulo Luiz Carvalho Francescantonio",
"url": "https://questionsmedicales.fr/author/Paulo%20Luiz%20Carvalho%20Francescantonio",
"affiliation": {
"@type": "Organization",
"name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil."
}
},
{
"@type": "Person",
"name": "Alessandra Dellavance",
"url": "https://questionsmedicales.fr/author/Alessandra%20Dellavance",
"affiliation": {
"@type": "Organization",
"name": "Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil."
}
},
{
"@type": "Person",
"name": "Luis Eduardo Coelho Andrade",
"url": "https://questionsmedicales.fr/author/Luis%20Eduardo%20Coelho%20Andrade",
"affiliation": {
"@type": "Organization",
"name": "Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br."
}
},
{
"@type": "Person",
"name": "Antônio Carlos Ximenes",
"url": "https://questionsmedicales.fr/author/Ant%C3%B4nio%20Carlos%20Ximenes",
"affiliation": {
"@type": "Organization",
"name": "Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The CardioMEMS Heart Failure System for chronic heart failure - a European perspective.",
"datePublished": "2023-04-18",
"url": "https://questionsmedicales.fr/article/37070597",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/17434440.2023.2196400"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Heart Failure Knights.",
"datePublished": "2023-05-26",
"url": "https://questionsmedicales.fr/article/37244515",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cpcardiol.2023.101834"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Heart failure and obesity].",
"datePublished": "2022-10-24",
"url": "https://questionsmedicales.fr/article/36286764",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.26442/00403660.2022.09.201837"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ferroptosis in heart failure.",
"datePublished": "2022-10-20",
"url": "https://questionsmedicales.fr/article/36273661",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.yjmcc.2022.10.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization.",
"datePublished": "2023-03-31",
"url": "https://questionsmedicales.fr/article/36961877",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14656566.2023.2195540"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cellules épithéliales",
"item": "https://questionsmedicales.fr/mesh/D004847"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hépatocytes",
"item": "https://questionsmedicales.fr/mesh/D022781"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cellules HepG2",
"item": "https://questionsmedicales.fr/mesh/D056945"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cellules HepG2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cellules HepG2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-01",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cellules HepG2",
"description": "Comment identifier les cellules HepG2 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les HepG2 ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Heart+Failure#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cellules HepG2",
"description": "Les cellules HepG2 présentent-elles des symptômes ?\nQuels marqueurs sont associés aux cellules HepG2 ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Heart+Failure#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cellules HepG2",
"description": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?\nComment les HepG2 contribuent-elles à la recherche préventive ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Heart+Failure#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cellules HepG2",
"description": "Peut-on utiliser HepG2 pour tester des médicaments ?\nComment les HepG2 aident-elles à développer des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Heart+Failure#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cellules HepG2",
"description": "Quelles complications peuvent être étudiées avec HepG2 ?\nLes HepG2 aident-elles à comprendre les complications du foie ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Heart+Failure#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cellules HepG2",
"description": "Quels facteurs de risque sont étudiés avec HepG2 ?\nComment HepG2 aide à identifier des facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Heart+Failure#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les cellules HepG2 en laboratoire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine."
}
},
{
"@type": "Question",
"name": "Quelles techniques sont utilisées pour étudier les HepG2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire."
}
},
{
"@type": "Question",
"name": "Les cellules HepG2 présentent-elles des symptômes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux cellules HepG2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques."
}
},
{
"@type": "Question",
"name": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Comment les HepG2 contribuent-elles à la recherche préventive ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser HepG2 pour tester des médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments."
}
},
{
"@type": "Question",
"name": "Comment les HepG2 aident-elles à développer des traitements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent être étudiées avec HepG2 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées."
}
},
{
"@type": "Question",
"name": "Les HepG2 aident-elles à comprendre les complications du foie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont étudiés avec HepG2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés."
}
},
{
"@type": "Question",
"name": "Comment HepG2 aide à identifier des facteurs de risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 05/02/2025
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com.
Publications dans "Cellules HepG2" :
5 publications dans cette catégorie
Affiliations :
School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil.
Publications dans "Cellules HepG2" :
4 publications dans cette catégorie
Affiliations :
Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil.
Publications dans "Cellules HepG2" :
4 publications dans cette catégorie
Affiliations :
Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br.
Immunology Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil. luis.andrade@unifesp.br.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Departamento de Patologia Clínica e Anatomia Patológica, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Department of Clinical Pathology, School of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Hermes Pardini Group, Vespasiano, MG, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Serviço de Reumatologia e Laboratório de Autoimunidade da Divisão de Laboratório Central do Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Sociedade Brasileira de Autoimunidade, Porto Alegre, RS, Brazil.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: liv880213@foxmail.com.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
Hainan Provincial Key Laboratory for Tropical Hydrobiology and Biotechnology, School of Marine Science, Hainan University, Haikou 570228, China. Electronic address: xiexi@hainu.edu.cn.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: 1532892231@qq.com.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: luolijie4567@163.com.
Publications dans "Cellules HepG2" :
Chronic heart failure (HF) is characterized by high hospital admission rates. The CardioMEMS...
This review focuses on safety and efficacy data for CardioMEMS remote hemodynamic monitoring in European HF setting, and discusses important upcoming studies....
For safety, data from European studies are in line with U.S. studies. Efficacy with regard to reduction of HF hospitalizations seems promising, but is merely based upon observational studies comparing...
The 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure (HF) have abandoned the sequential approach for optimal drug therapy and proposed ...
Obesity is an independent predictor of cardiovascular diseases (CVD), including heart failure (HF). Nevertheless, numerous studies have shown that patients with CVD who are overweight and slightly obe...
With its complicated pathobiology and pathophysiology, heart failure (HF) remains an increasingly prevalent epidemic that threatens global human health. Ferroptosis is a form of regulated cell death c...
Worsening heart failure (HF) is associated with a high risk of death and HF hospitalization....
A systematic search was conducted on PubMed (MEDLINE), using the MeSH terms [Heart failure] + [Worsening] + [Treatment] + [Vulnerable period] up to February 2023. Original data from clinical trials, a...
Although the vulnerable period has been traditionally limited to the first 6 months after HF hospitalization, the fact is that there are other clinical scenarios in which the patient is particularly v...
Pulmonary vascular resistance (PVR) is critical when evaluating candidacy for advanced heart failure (HF) therapies, but risk factors for elevated PVR are not well studied. We hypothesized that HF dur...
Danish single-center registry of consecutive in- and outpatients undergoing right heart catheterization as part of advanced HF work up. The relation between HF duration and PVR was estimated by regres...
A total of 549 patients (77% men, median age 54 (43-61) years, median HF duration 1.6 years (0.1-7.1)) were included. Univariate linear regression displayed an association between longer HF duration a...
Longer duration of HF was associated with higher PVR in patients with advanced HF, but this association disappeared in multivariate analyses. Longer HF duration per se likely does not cause elevated P...
Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (H...
Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (H...
In the CANVAS (Canagliflozin Cardiovascular Assessment Study) program, canagliflozin reduced the risk of heart failure (HF) hospitalization among individuals with type 2 diabetes mellitus (T2DM)....
The purpose of this study was to evaluate heterogeneity in absolute and relative treatment effects of canagliflozin on HF hospitalization according to baseline HF risk as assessed by diabetes-specific...
Participants in the CANVAS trial were categorized into low, medium, and high risk for HF using the WATCH-DM score (for participants without prevalent HF) and the TRS-HF...
Among 10,137 participants with available HF data, 1,446 (14.3%) had HF at baseline. Among participants without baseline HF, WATCH-DM risk category did not modify the treatment effect of canagliflozin ...
Among participants with T2DM, the WATCH-DM and TRS-HF...
Randomized controlled trials have demonstrated mortality benefits for several medication classes in patients with heart failure (HF), especially with reduced ejection fraction (EF). However, the benef...